• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » HeartWare jumps on bridge-to-transplant study results

HeartWare jumps on bridge-to-transplant study results

October 3, 2011 By MassDevice staff

HeartWare

Shares of HeartWare International Inc. (NSDQ:HTWR) rose nearly 5 percent today after an update on a bridge-to-transplant trial of its implantable heart pump showed 93 percent of the 241 patients survived for at least six months after receiving the device.

The Framingham, Mass.-based firm presented the results from the Advance BTT study and its continued access protocol arm at the European Assn. for Cardio-Thoracic Surgery’s annual meeting in Lisbon.

The patients in the trial – 140 from Advance and another 101 with at least six months follow-up – are part of HeartWare’s investigational device exemption from the FDA to study the device as a temporary bridge for patients awaiting a heart transplant.

Sign up to get our free newsletters delivered straight to your inbox

"Consistent with previously presented data from this study, we observed high survival rates for patients through the six-month endpoint, and particularly low observed rates for bleeding and infection," said principal investigator Dr. Mark Slaughter in prepared remarks. "Adjustments in anticoagulation are contributing to reduced thrombus events, and overall adverse event rates remain low despite increased exposure to the device due to higher survival and a lower transplant rate."

The reduced thrombus events Slaughter cited are likely mollifying some Wall Street investors who were spooked by a higher-than-expected rate of blood clots in the trial. That update sent shares down 15 percent in mid-April.

Today HeartWare said only 0.03 percent of patients in the trial needed to have a pump replaced for suspected thrombus, down "since an adjustment in anticoagulation in March," according to a press release.

The company is also enrolling patients for a 450-patient study of the HVAD pump as a so-called "destination therapy" for patients too sick or otherwise ineligible for a heart transplant. Once enrollment wraps up by mid-2012, the company hopes, those patients will be tracked for two years post-implantation.

HeartWare is on the short list of potential acquisitions by Swiss investment bank UBS, along with rivals Thoratec Corp. (NSDQ:THOR) and Abiomed (NSDQ:ABMD). One potential acquirer is Johnson & Johnson (NYSE:JNJ), which has expressed interest in the cardiac assist device space in recent weeks.

HTWR shares closed at $67.46 today, up 4.7 percent from yesterday’s close.

Filed Under: News Well, Structural Heart, Wall Street Beat Tagged With: Clinical Trials, HeartWare International Inc.

More recent news

  • Data backs Medtronic MiniMed 780G for type 2, children as company seeks expanded indications
  • Endogenex data supports type 2 diabetes procedure
  • Ambu wins FDA clearance for first single-use cysto-nephroscope
  • Tandem Diabetes Care pairs t:slim X2 pump with Abbott FreeStyle Libre 3 Plus in U.S.
  • Ypsomed, CamDiab to integrate Abbott dual glucose-ketone sensor into automated insulin delivery system

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy